In the larger SELECT trial in 2023, patients with heart failure, atherosclerotic disease, and overweight or obesity, treated with semaglutide 2.4 mg showed reduction in major adverse cardiac events (MACE) and heart failure end points regardless of heart failure subgroup being HFrEF or HFpEF [56,57,58]
Heres what you need to know: What Are GLP-1 Medications
DiMarchi conoce bien estos frmacos: fue pionero en la investigacin de esta clase de compuestos a finales de los aos 90, cuando trabajaba en Eli Lilly como vicepresidente del grupo de investigacin y desarrollo
Retatrutide (LY3437943) is a first-in-class triple-receptor agonist peptide developed by Eli Lilly that simultaneously activates three metabolic receptors: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon
What is regular (brand-name) tirzepatide
Retatrutide Research Peptide (Lyophilised, HPLC 99%) 59.00